AstraZeneca has announced the results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type 2 diabetes at a wide range of CV risk.

The drug was found not to increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack or non-fatal stroke, compared to placebo. There were also fewer CV events observed in the exenatide arm of the trial.

Recommended

Study highlights codeine dependence – a problem for pharmacy?

Pharmacies are a common source of codeine for dependent people but only one in 50 users seeks a pharmacist’s support

Statins cut CV mortality

Pravastatin reduces long-term cardiovascular mortality by more a quarter, even in men with markedly raised LDL-C levels

Popular

Price concession delays added to contractor stress

Not all of the requested concession prices for the November dispensing month have been granted, says PSNC

Half of Brits take prescription drugs daily

Almost half of UK adults have taken at least one prescribed medicine in the last week, according to a new survey commiss...

Link between physical activity and wellbeing

A clear link between physical activity and mental wellbeing has been proven by a Sport England survey.